p53-binding protein 1 (53BP1) acts as an 'adaptor/ mediator' for transducing DNA damage signals, especially following detection of DNA double-strand breaks.
Introduction
Cellular DNA is continuously damaged by endogenous and exogenous insults such as oxygen radicals, ultraviolet radiation and various chemicals. Cells with damaged DNA activate cell cycle checkpoint mechanisms to allow DNA repair or induce apoptosis. The most severe form of DNA damage is a DNA double-strand break (DSB), which can be caused by ionizing radiation (IR) or chemicals such as camptothecin, a topoisomerase I inhibitor. DNA damage signals activate proximal kinases, including ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) kinases, which in turn activate various effector molecules involved in DNA damage repair, cell cycle arrest and induction of apoptosis (Zhou and Elledge, 2000; Khanna and Jackson, 2001 ). In the process of effector activation by proximal kinases, several proteins have been proposed to function as 'adaptors/mediators', which recruit effector molecules and facilitate their phosphorylation by proximal kinases (Melo and Toczyski, 2002) . Proposed adaptor molecules include p53-binding protein 1 (53BP1) (Wang et al., 2002) , mediator of DNA damage checkpoint protein 1 (MDC1) (Goldberg et al., 2003; Peng and Chen, 2003; Stewart et al., 2003) and BRCA1 (Yarden et al., 2002) in mammalian cells, and Rad9 (Emili, 1998; Sun et al., 1998; Vialard et al., 1998) in budding yeast. All of these proteins contain BRCA1 carboxy-terminal (BRCT) domains.
53BP1, which was originally identified as a binding protein of p53 (Iwabuchi et al., 1994) , has been proposed to function as an adaptor protein based on the following observations. 53BP1 can be phosphorylated by ATM kinase (Xia et al., 2001) and is required for IR-induced phosphorylation of ATM substrates including Chk2, BRCA1 and SMC1 (DiTullio et al., 2002; Wang et al., 2002) . Furthermore, 53BP1 is recruited to regions of DNA damage, where it forms IR-induced nuclear foci (Schultz et al., 2000; Anderson et al., 2001; Rappold et al., 2001) . It is possible that the identification and functional study of putative 53BP1-interacting proteins might broaden our understanding of the signaling pathways involved in activation of eucaryotic DNA damage signaling.
In this report, we identified replication protein A (RPA) complex as the 53BP1-interacting proteins in immunoprecipitation and mass spectrometric approach. RPA, a ubiquitous single-stranded DNA-binding protein complex that is required for DNA replication, repair and recombination (Wold, 1997; Iftode et al., 1999) , is composed of three subunits of 70, 34 and 14 kD (RPA1, RPA2 and RPA3, respectively) (Fairman and Stillman, 1988; Wold and Kelly, 1988) . Among the three subunits, RPA2 is phosphorylated from the G1-S phase transition to late mitosis (Din et al., 1990) . The RPA2 hyperphosphorylation also occurs in DNA damage response after IR (Liu and Weaver, 1993) , UV radiation (Carty et al., 1994) and treatment with anticancer drugs such as camptothecin (Shao et al., 1999) . Phosphatidyl inositol 3-kinase-like kinases such as DNA-PK and ATM have been implicated in this hyperphosphorylation event (Shao et al., 1999; Wang et al., 2001) . Here, we present evidences suggesting that 53BP1 is involved in camptothecin-induced RPA2 hyperphosphorylation and that inhibition of 53BP1 function may sensitize cancer cells to camptothecin treatment.
Results

Isolation of 53BP1-associating proteins
In an effort to identify 53BP1-interacting proteins, we isolated 53BP1-containing complexes by overexpression of HA-tagged 53BP1 followed by immunoprecipitation ( Figure 1b) . As a control, empty vector-transfected lysates were immunoprecipitated with anti-HA antibody ( Figure 1a ). Immunoprecipitates were subjected to twodimensional gel electrophoresis, and tryptic digests of protein spots present only in the 53BP1 immunoprecipitation were analysed by tandem mass spectrometry. Among them, two spots (#1 and #3) were identified as RPA1 and RPA2. Other identified protein spot (#2) was Ku80, a component of DNA-PK complex. The presence of RPA2 and Ku80 in the 53BP1-containing complexes was confirmed by immunoprecipitation followed by immunoblotting with cognate primary antibodies (Figure 2 ). Furthermore, we confirmed that other component of the DNA-PK complex, Ku70 was also present in the 53BP1 immunoprecipitates (data not shown). Analysis of co-immunoprecipitates of the amino-terminal (53BP1-N) or carboxyl-terminal (53BP1-C) half of 53BP1 revealed that the association was mediated through the carboxy-terminal half of the protein, which contains the BRCT domain.
Association between 53BP1 and RPA2 is disrupted upon DNA damage DNA-PK has been reported to phosphorylate RPA2 in response to treatment of cells with camptothecin, a topoisomerase I inhibitor (Shao et al., 1999) . Based on this, identification of components of RPA complex and DNA-PK complex as 53BP1-associating proteins made us to postulate that 53BP1 might function as an adaptor protein for camptothecin-induced RPA2 hyperphosphorylation. We first examined whether the association between 53BP1 and RPA2 was affected by camptothecin treatment. Co-immunoprecipitation experiments revealed that the specific interaction between overexpressed HA-53BP1 and endogenous RPA2 (Figure 3a , lane 2) was disrupted 2 h after treatment with 3 mM camptothecin ( Figure 3a, lane 3) . A similar phenomenon was observed when we monitored the presence of Proteins were resolved by two-dimensional gel electrophoresis consisting of isoelectric focusing (IEF) on a nonlinear pH gradient from 3 to 10, followed by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Protein spots present only in the 53BP1 IP were analysed by tandem mass spectrometry. #1, #2 and #3 indicate spots identified as RPA1, Ku80 and RPA2, respectively . Co-immunoprecipitation experiment between endogenous 53BP1 and RPA2 also revealed the disruption of the interaction after camptothecin treatment ( Figure 3c ). Furthermore, confocal microscopic study substantiated the presence of a dynamic interaction between the two proteins ( Figure 3d ). They exhibited dispersed localization throughout the nucleus in untreated U2OS osteosarcoma cells ( Figure 3d , top panels) and formed discrete foci after treatment with camptothecin ( Figure 3d , bottom panels). However, the foci of 53BP1 and RPA2 did not coincide to each other.
RPA2 hyperphosphorylation is inhibited by stable transfection of dominant-negative fragments of 53BP1
To investigate the functional relationship between 53BP1 and RPA2, we established U2OS cell lines (N11 and C30) stably expressing the amino-terminal (53BP1-N) or carboxy-terminal (53BP1-C) half of 53BP1, respectively ( Figure 4a ). It has been demonstrated that both fragments of 53BP1 would exert dominantnegative effects on 53BP1 function, based on the observations that their overexpression abolished the T68 phosphorylation of Chk2 by ATM (unpublished data). The established cell lines were treated with 3 mM camptothecin for 1 and 2 h, and immunoblotting was performed to detect hyperphosphorylated RPA2 as an electrophoretic-mobility-shifted band ( Figure 4b ). In control PC cells, the hyperphosphorylated form of RPA2 (P-RPA2) appeared 1 h after camptothecin treatment. In contrast, no mobility-shifted bands were detected at this time point in N11 and C30 cells. Even though RPA2 hyperphosphorylation occurred after 2 h treatment with campothecin in these dominant-negative cell lines, the extent of RPA2 phosphorylation was significantly lower than that in PC cells. This result . Experiments were performed as in panel a except that endogenous RPA2 was immunoprecipitated with anti-RPA2 antibody and endogenous 53BP1 was detected by immunoblotting. (d) Localization of RPA2 and 53BP1 after camptothecin treatment. U2OS cells were treated with 3 mM camptothecin (CPT) or DMSO (None) for 2 h. After being fixed in paraformaldehyde, cells were incubated with anti-53BP1 and anti-RPA2, and then with Alexa 488-conjugated anti-rabbit (for 53BP1 detection) and Texas Red-X-conjugated anti-mouse (for RPA2 detection). Cells were observed under a Zeiss axiovert LSM510 microscope
implies that 53BP1 is involved in RPA2 phosphorylation after camptothecin treatment. Similarly, RPA2 phosphorylation after ionizing radiation was also inhibited in 53BP1 dominant-negative cell lines (Figure 4c ).
Decreasing the 53BP1 expression levels inhibits the RPA2 hyperphosphorylation
To confirm the involvement of 53BP1 in RPA2 hyperphosphorylation in response to DNA damage, 53BP1 expression was knocked down by direct transfection of 53BP1-specific siRNAs (Figure 4d ). Compared with the control siRNA transfection (GL2), knockdown of 53BP1 significantly inhibited camptothecin-induced RPA2 phosphorylation (Figure 4d , lane 5). We also checked the possibility that other DNA damage signaling adaptor protein like MDC1 (Goldberg et al., 2003; Stewart et al., 2003) may be involved in the RPA2 hyperphosphorylation. Interestingly, MDC1 siRNA did not inhibit the hyperphosphorylation, even though MDC1 levels significantly decreased (Figure 4d , lane 6).
Camptothecin-induced apoptosis was augmented by inhibition of 53BP1
Next, we checked the camptothecin sensitivities of 53BP1 dominant-negative cell lines by MTT assay (Figure 5a ). Both N11 (Figure 5a , triangles) and C30 cells (Figure 5a , rectangles) were clearly more sensitive to camptothecin treatment, as compared to control PC cells (Figure 5a, diamonds) . A similar increase in camptothecin sensitivity was observed in cells transiently transfected with 53BP1 siRNA, as compared with cells transfected with GL2 control siRNA (Figure 5b) . Again, MDC1 siRNA transfection did not result in increased drug sensitivity, consistent with the observed lack of inhibitory effect of this siRNA on RPA2 hyperphosphorylation. When the DNA contents of camptothecin-treated N11 and C30 cells were compared with those of control cells by flow cytometry, the percentages of sub-G1 fractions were two-to three-fold higher in N11 and C30 cells than in control cells (Figure 5c ). This result suggests that the drug sensitivities of 53BP1 dominant-negative cell lines are due to enhancement of camptothecininduced apoptosis in these cell lines. Increased apoptosis in 53BP1 dominant-negative cells was further confirmed by detecting the cleavage product (p85 denoted by arrowhead) of poly(ADP-ribose) polymerase (PARP) by caspase 3 during apoptosis (Figure 5d ). We found that the PC cells had significant amounts of uncleaved PARP 2 days after camptothecin treatment. In contrast, most of the PARP in N11 and C30 cells was cleaved by 1 day after camptothecin treatment. To see the effect of 53BP1 disturbance on the longterm cell survival after camptothecin treatment, clonogenic assay was performed (Figure 5e ). The result clearly shows the reduced survival of 53BP1 dominant-negative cell lines compared with that of the control PC cells. Together, the above results strongly imply that inhibiting 53BP1 function can enhance camptothecin-induced apoptosis, resulting in increased cellular sensitivity to the drug.
Discussion
In this study, mass spectrometric analysis of 53BP1-containing protein complexes was performed to identify the RPA complex as being associated with 53BP1 ( Figure 1) . Based on the proposed role of 53BP1 as an 'adaptor/mediator' in DNA damage signaling pathway (Wang et al., 2002) and the reports that RPA2 is hyperphosphorylated by the actions of DNA-PK and/or Figure 5 Camptothecin-induced apoptosis was augmented by inhibition of 53BP1. (a) Camptothecin cytotoxicity was enhanced in 53BP1 dominant-negative cell lines. PC (E), N11 (m) and C30 (') cells were treated with various concentrations of camptothecin for 3 days. Cell proliferation and survival was measured by MTT assay. The Y-axis represents the percentage of cell proliferation compared with that in untreated cells. Similar results were observed in three independent experiments. (b) Cellular sensitivity to camptothecin was enhanced by transient transfection of 53BP1-specific siRNA. U2OS cells were transiently transfected with 53BP1 (') or MDC1 (m) siRNAs. GL2 siRNAs were used as the control (E). After 24 h, cells were treated with various concentrations of camptothecin, and MTT assays were performed after 4 days. Similar results were obtained in three independent experiments. (c) Camptothecin-treated 53BP1 dominant-negative cell lines exhibited increased apoptosis. PC, N11 and C30 cells were treated with 3 mM camptothecin for 2 days, harvested and treated with propidium iodide. Cellular DNA contents were analysed by flow cytometry. The Y-axis represents the percentages of sub-G1 fractions. (d) Camptothecin-induced PARP fragmentation was enhanced in 53BP1 dominant-negative cell lines. Cells were treated with 3 mM camptothecin for 1, 2 or 3 days and immunoblotted with anti-PARP antibody. In all, 85 kD PARP fragments are marked by an arrowhead. b-Actin levels show equivalent loading of cell lysates. (e) 53BP1 dominant-negative cell lines exhibited reduced long-term survival after camptothecin treatment. Long-term survival was determined by clonogenic assay. PC (E), N11 (m) and C30 (') cells were plated to 60-mm dishes, treated with various concentrations of camptothecin for 16 h, rinsed twice and then refed with fresh medium. After 14 days, cells were fixed and stained with 0.1% crystal violet solution. Surviving fractions were determined based on plating efficiencies Involvement of 53BP1 in RPA2 hyperphosphorylation E Yoo et al ATM following DNA damage (Shao et al., 1999; Wang et al., 2001) , we hypothesized that 53BP1 might be involved in RPA2 phosphorylation. The association between 53BP1 and RPA2 was disrupted after DNA damage induction by camptothecin treatment (Figure 3 ). RPA2 hyperphosphorylation after camptothecin treatment was inhibited in 53BP1 dominant-negative cell lines overexpressing fragments of the 53BP1 molecule or in cells transiently transfected with 53BP1-specific siRNA (Figure 4 ). This result strongly implies that 53BP1 is required for RPA2 phosphorylation. However, siRNA transfection study suggests that other BRCTcontaining adaptor protein MDC1 may not be involved in RPA2 phosphorylation (Figure 4d) .
Within the context of camptothecin-induced RPA2 phosphorylation, 53BP1 may act as an adaptor/mediator for recruiting upstream kinases to the substrate, RPA2. Candidates for upstream kinases include phosphotidylinositol 3-kinase-like kinases such as ATM and DNA-PK. These kinases can phosphorylate RPA2 in vitro (Niu et al., 1997; Zernik-Kobak et al., 1997; Gately et al., 1998) and have been implicated in RPA2 phosphorylation following DNA damage (Shao et al., 1999; Wang et al., 2001 ). Although we do not yet know which RPA2-phosphorylating kinase is affected by 53BP1, ATM is a good possibility based on the fact that 53BP1 physically interacts with ATM (DiTullio et al., 2002) , and is required for the phosphorylation of various ATM substrates, including Chk2 (Wang et al., 2002) . However, other reports have indicated that RPA2 hyperphosphorylation is carried out by DNA-PK during the cellular response to camptothecin, an inducer of replication-dependent DNA DSBs (Shao et al., 1999) . Our demonstration of an association between 53BP1 and components of DNA-PK (Figure 2 ) strongly implies that 53BP1 might function cooperatively with DNA-PK in RPA2 phosphorylation.
In general, the DNA damage pathway is considered a good target for chemosensitization strategies. Previously, alterations of genes encoding DNA damage pathway proteins, such as ATM, NBS1 and BRCA1, have been reported to render mammalian cells more sensitive to topoisomerase I inhibitors (Smith et al., 1989; Kraakman-van der Zwet et al., 1999; Fedier et al., 2003) . In this study, 53BP1 inhibition by dominantnegative constructs or siRNA transfection rendered osteosarcoma cells more sensitive to camptothecin by enhancing apoptosis (Figure 5 ). This result may serve as the basis for further work on targeting 53BP1 to sensitize cancer cells to topoisomerase I inhibitor anticancer drugs, such as topotecan and irinotecan currently used for the therapy of colon, ovarian and lung cancer patients (Pizzolato and Saltz, 2003) .
Materials and methods
Cells
U2OS osteosarcoma cells and 293T human embryonic kidney cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Gibco) at 371C in a humidified incubator supplied with 5% CO 2 .
Constructs
53BP1
expression plasmids pCMH6K53BP1, pCMH6K53BP1-N and pCMH6K53BP1-C were kindly provided by Dr Stanley Fields of University of Washington, WA, USA (Iwabuchi et al., 1998) . For construction of the RPA2 expression plasmid, pV5-RPA2, the RPA2 cDNA was RT-PCR amplified from 293T total RNA using M-MLV reverse transcriptase (Promega) and Pfu polymerase (Stratagene). The resulting fragment was inserted into the EcoRI/XhoI site of pcDNA3, which has a V5 tag sequence (GKPIPNP LLGLDST) upstream of the EcoRI site. The primer sequences used for RT-PCR were 5 0 -TTGCGGAATTCCGTGACC-3 0 and 5 0 -CCCAGTTAGCTCG AGTTATTCTGC-3 0 , corresponding to À21 to À4 and 1096 to 1119 of the RPA2 cDNA sequence respectively.
Immunoprecipitation
293T cells were transfected with pCMH6K53BP1, pCMH6K53BP1-N or pCMH6K53BP1-C, using the Effectenet reagent (Qiagen) according to the manufacturer's instructions. Cell lysates were prepared as previously described (Lee and Chung, 2001) and precleared with Protein Aconjugated agarose beads (Gibco/BRL). HA-tagged 53BP1 (HA-53BP1) was immunoprecipitated with 1 mg of anti-HA antibody (Covance) and 10 ml of Protein A-agarose for 16 h at 41C. Samples were washed twice with lysis buffer (50 mM TrisCl, pH 7.4, 150 mM NaCl, 0.3% Igepal CA630, 0.2% Triton X-100, 1 mM sodium orthovanadate and a protease inhibitor complete tablet from Roche), and then separated by twodimensional gel electrophoresis.
Two-dimensional gel electrophoresis
After the beads were washed, they were mixed with 125 ml of rehydration buffer (8 M urea, 4% CHAPS, 100 mM DTT, 0.5% IPG buffer, 40 mM Tris-Cl and 0.002% bromophenol blue). After vigorous vortexing and centrifugation, the samples were applied to 7 cm IPG strips with a nonlinear pH gradient of 3 to 10 (Amersham Biosciences) for 12 h. Isoelectric focusing was performed at 500 V for 30 min, at 1000 V for 30 min and finally at 8000 V for 2 h. Strips were placed in sodium dodecylsulfate (SDS) equilibration buffer (375 mM Tris-Cl, pH 8.8, 6 M urea, 20% glycerol, 2% SDS, 5 mM Tributyl phosphine, 2.5% acrylamide and 0.002% bromophenol blue) for protein denaturation, and second dimension electrophoresis was performed on 10% SDS-polyacrylamide gels. The protein spots were visualized with silver nitrate staining.
Tryptic digestion and mass spectrometry
Gel slices containing protein spots of interest were excised in approximately 1 mm 3 cubes, and soaked in 100 ml of 15 mM potassium ferricyanide and 50 mM sodium thiosulfate for 10 min. The gel slices were washed three times in water and three times in 50% acetonitrile/25 mM ammonium bicarbonate (pH 8.0), dehydrated in 100% acetonitrile for 5 min, and then dried in a Speed-Vac for 30 min. Trypsin (15 mg/ml in 25 mM ammonium bicarbonate, pH 8.0) was added to the gel slices and incubated at 371C for 20 h. Tryptic peptides were extracted by soaking gel slices in 50% acetonitrile/5% trifluoroacetic acid (TFA) for 30 min, and samples were dried in a Speed-Vac. Peptides were dissolved in 40% acetonitrite/0.1% TFA, mixed with gentisic acid at a concentration of 10 mg/ml and finally spotted onto a MALDI plate. Tandem mass spectrometric analysis of the tryptic peptides was performed using a MALDI/QSTARt apparatus (Applied Biosystems). Protein identification was achieved by Swiss-prot protein database search with mass tolerance of 50 part per million (ppm).
Immunoblotting
Cell lysates or immunoprecipitates were subjected to 4-12% Tris-glycine polyacrylamide gel electrophoresis, and the separated proteins were transferred to nitrocellulose membranes (BA83, Schleicher & Schyell) and blocked in 5% skim milk in PBST (PBS supplemented with 0.2% Tween 20). The membranes were then probed with the appropriate antibodies, including anti-53BP1 (Novus Biologicals), anti-HA (Covance), anti-RPA2 (Calbiochem), anti-Ku70 (Santa Cruz Biotechnology), anti-Ku80 (Pharmingen), anti-MDC1 (Abcam), b-actin (Sigma-Aldrich) and anti-PARP (Santa Cruz Biotechnology).
Immunofluorescence microscopy U2OS cells were grown on coverslips to 50% confluence and treated with 3 mM of (S)-( þ )-camptothecin (Sigma-Aldrich) for 2 h. Cells were fixed in 3.7% paraformaldehyde in PBS for 15 min, permeabilized with 0.2% Triton X-100 in PBS for 10 min and blocked with 1% BSA in PBS for 1 h. The fixed cells were incubated for 2 h with anti-53BP1 and anti-RPA2 as primary antibodies, and then washed in PBS and incubated with Alexa 488-conjugated anti-rabbit and Texas Red-Xconjugated anti-mouse antibodies for 1 h. Cells were washed in PBS, mounted on glass slides and observed with a Zeiss axiovert LSM510 microscope.
Generation of 53BP1 dominant-negative cell lines
For development of 53BP1 dominant-negative cell lines, U2OS cells were cotransfected with pCMH6K53BP1-N or pCMH6K53BP1-C along with pMamNeo (Clontech) at a ratio of 5 : 1. At 2 days post-transfection, stably transfected cells were selected with 1 mg/ml G418 sulfate until distinct colonies emerged. The resistant colonies were propagated and examined for expression of HA-tagged fragments of 53BP1.
MTT assay U2OS cells (1 Â 10 3 ) were seeded in a 96-well plate and camptothecin was added to final concentrations as indicated. After 72 or 96 h, 100 ml of 0.5 mg/ml 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) solution in DMEM was added per well. The purple formazan crystals were allowed to develop for 3 h at 371C. The MTT-containing medium was then removed and 100 ml of dimethyl sulfoxide was added to each well. Absorbance at 570 nm was measured in a microplate reader (Bio-Tek).
Flow cytometry
Cells were washed with PBS and fixed in 50% ethanol. Fixed cells were washed once with PBS supplemented with 0.1% Triton X-100 and resuspended in 300 ml of cold PBS. RNase A (5 ml; 10 mg/ml) was added and the cell suspensions were incubated for 15 min at room temperature. Propidium iodide was added at a concentration of 77 mg/ml and incubated for 30 min on ice. The cellular DNA contents were analysed by flow cytometry using FACSCalibur flow cytometer.
Clonogenic assay
Long-term survival was determined by a colony-forming assay. A total of 1000 cells were plated to 60-mm dishes. At 24 h after plating, cells were treated with 0, 6.25, 12.5, 25 and 50 nM camptothecin for 16 h. Cell monolayers were rinsed twice and then refed with fresh medium. After 14 days, cells were fixed and stained with 0.1% crystal violet solution. Colonies consisting of >50 cells were counted, and surviving fractions were determined based on plating efficiencies. Experiments were performed in triplicate.
siRNA transfection
The siRNA duplexes consisted of 21 base pairs with a 2-base deoxynucleotide overhang (Dharmacon Research). The sequences of the 53BP1 siRNA and MDC1 siRNA were GCCAGGUUCUAGAGGAUGAdTdT and UCCUGA-GACCUCCUAA GGUdTdT, respectively (Goldberg et al., 2003) . The control siRNA, GL2 (Dharmacon Research; CGUACGCGGAAUACUUCGAdTdT) was directed against the luciferase gene. U2OS cells were transfected with siRNA duplexes using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Briefly, 160 pmol of siRNA and 4 ml of Lipofectamine 2000 were added separately to 200 ml of DMEM. After 5 min, the two solutions were mixed and incubated for 20 min at room temperature. Mixtures were added to U2OS monolayers fed with fresh media.
